logo
Plus   Neg
Share
Email

Opdivo Plus Chemotherapy As Neoadjuvant Treatment In Resectable NSCLC Trial Hits Key Goal, Says BMY

Bristol Myers Squibb's (BMY) phase III study investigating its blockbuster drug Opdivo in combination with chemotherapy as *neoadjuvant treatment of resectable non-small cell lung cancer, dubbed CheckMate 816, has met the primary endpoint of pathologic complete response.

In the ongoing phase III trial, 358 patients were randomized to receive either Opdivo 360 mg plus histology-based platinum doublet chemotherapy every three weeks for up to three doses, or platinum doublet chemotherapy alone every three weeks for up to three doses, followed by surgery.

A primary analysis of the trial has shown that significantly more patients treated with Opdivo plus chemotherapy before surgery showed no evidence of cancer cells in their resected tissue compared to those treated with chemotherapy alone. CheckMate -816 is the first and only Phase 3 trial to demonstrate a benefit with an immune checkpoint inhibitor in combination with chemotherapy as a neoadjuvant treatment in non-metastatic NSCLC, the company noted.

The other primary endpoint of event-free survival (EFS) and key secondary endpoints of the trial are yet to be assessed.

Bristol Myers' Opdivo is approved for the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma.

In the second quarter ended June 30, 2020, Opdivo recorded sales of $1.65 billion, down 9% from the year-ago quarter.

* Neoadjuvant treatment is the treatment given before surgery.

BMY is currently trading at $58.44, up 1.22%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
American Airlines announced the launch of Flagship Cellars, its home delivery service for premium wines usually available onboard. The airline's move is said to be due to the excess wine it has amid the weakness in air travel demand following the coronavirus pandemic crisis. The company expects the new at-home wine program to generate about $40,000 to $50,000 in sales during the first quarter. Intel Corp. is planning to manufacture majority of its 2023 products internally, while it may outsource some, according to the incoming Chief Executive Officer Pat Gelsinger. At the fourth-quarter earnings webcast, while talking about 7nm program development, Gelsinger said, "I am confident that the majority of our 2023 products will be manufactured internally...." American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until March 31 in response to lower travel demand due to the coronavirus pandemic. This means that travelers are provided additional flexibility by not asking them to pay penalties for changing the origin and destination cities.
Follow RTT